Cell wall active bacteriocins and their applications beyond antibiotic activity

Clara Roces, Ana Rodríguez and Beatriz Martínez*

DairySafe group. Department of Technology and Biotechnology of Dairy Products.

Instituto de Productos Lácteos de Asturias, IPLA-CSIC. Paseo Río Linares s/n. 33300
Villaviciosa, Asturias, Spain.

* Corresponding Author

Beatriz Martínez

IPLA-CSIC

Paseo Río Linares s/n.

33300 Villaviciosa, Asturias, Spain.

Phone: + 34 985 89 33 59

Fax: +34 985 89 22 33

E-mail: bmfl@ipla.csic.es

Abstract

Microorganisms synthesize several compounds with antimicrobial activity in order to compete or defend themselves against others and ensure their survival. In this line, the cell wall is a major protective barrier whose integrity is essential for many vital bacterial processes. Probably for this reason, it represents a ‘hot spot’ as a target for many antibiotics and antimicrobial peptides such as bacteriocins. Bacteriocins have largely been recognized by their pore forming ability that collapses the selective permeability of the cytoplasmic membrane. However, in the last few years, many bacteriocins have been shown to inhibit cell wall biosynthesis either in a concerted action with pore formation, e.g. nisin, or not. Examples of cell wall-active bacteriocins are found in both Gram-negative and in Gram-positive bacteria and include a wide diversity of structures such as nisin-like and mersacidin-like lipid II-binding bacteriocins, two peptide lantibiotics and non-modified bacteriocins. In this review, we summarize the current knowledge on these antimicrobial peptides as well as the role, composition and biosynthesis of the bacterial cell wall as their target. Moreover, even though bacteriocins have been a matter of interest as natural food antimicrobials, we propose them as suitable tools to provide new means to improve biotechnologically relevant microorganisms.

Keywords: bacteriocins, mode of action, peptidoglycan, lipid II, cell envelope stress

41 **Introduction**

42 All living organisms produce some kind of inhibiting substances as part of their defense or
43 immune system in order to thrive in a competing niche. In particular, microbial antagonism
44 is well documented and production of antimicrobials includes antibiotics, lytic enzymes,
45 low-molecular weight metabolites such as organic acids, toxins, and bacteriocins.

46 Bacteriocins are ribosomally-synthesized antimicrobial peptides or proteins produced by
47 bacteria with inhibitory (bactericidal or bacteriostatic) activity against species closely
48 related to the producer (narrow spectrum), or active beyond the genus boundary (broad
49 spectrum). Although bacteriocin production is not an essential trait in bacteria, it is
50 evolutionary maintained and widely distributed even though it entails biological costs.

51 Indeed, it is estimated that around 99 % of bacterial species produce bacteriocins and even
52 within a species, different bacteriocins can be synthesized [72, 113]. Some bacteriocins
53 have been shown to be involved in competition among bacterial strains, niche colonization,
54 and in quorum sensing and communication [32, 34, 51, 118].

55 Bacteriocins comprise a very heterogenous group regarding their primary structure and
56 physico-chemical properties. Likewise, there is a plethora of modes of action targeting
57 DNA replication, transcription, translation, enzymatic reactions, cell wall biosynthesis or
58 the cytoplasmic membrane. Disruption of the selective permeability of the membrane by
59 pore formation is a common inhibitory mechanism for cationic antimicrobial peptides
60 which are virtually produced by all forms of life [146], including many bacteriocins
61 synthesized by Gram-positive bacteria (i.e. pore-forming bacteriocins). However, a striking
62 feature of pore-forming bacteriocins, when compared to their eukaryotic counterparts, is
63 their high specific activity at the nanomolar range and their relatively limited spectrum of

activity. This is explained now by the increasing evidence that many of the pore-forming bacteriocins make target-mediated pores rather than being membrane disruptors. This holds true for several non-modified bacteriocins that use the membrane-associated component of the mannose-phosphotransferase system as a specific receptor [40, 72]. Another example is the use of the cell wall precursor lipid II as a docking molecule for pore formation, combining inhibition of cell wall biosynthesis with the formation of pores [19, 23]. Moreover, several non-pore forming bacteriocins targeting the cell wall have been described able to either hinder cell wall biosynthesis or hydrolyze pre-existing peptidoglycan. Based on its essential nature, the biosynthetic pathway of the cell wall has been, and still is, a validated target in antibiotic development [25, 129]. In view of the need of novel antimicrobials, cell wall-active bacteriocins are foreseen as a source of novel structures and activities which may represent new leads for antibiotic development. This review will focus on cell wall-active bacteriocins synthesized by both Gram-positive and Gram-negative bacteria. Moreover, examples are given on how these bacteriocins may be used as tools to improve biotechnological processes by enhancing the performance of the microorganisms involved.

Bacteriocin diversity and classification: a constant debate

Bacteriocin production is a widespread trait among bacteria, and some species of Archaea also produce their own bacteriocin-like compounds called archaeocins [100, 113]. These are reported to be very resistant to extreme conditions with very promising applications.

86 However, little is known about their mode of action and they will not be covered in this
87 review.

88 Among bacteriocins synthesized by Gram-negative bacteria, colicins and microcins,
89 produced by *Escherichia coli* and mostly active against Gram-negative microorganisms,
90 have been extensively studied. Colicins are large proteins (25-80 kDa), usually plasmid-
91 borne that encodes a toxin gene, an immunity gene and, in some cases, a stress-induced
92 lysis gene. The latter encodes a protein that lyses the producer cell to release the colicin
93 into the environment. When this gene is absent, the bacteriocin is actively transported
94 across the membrane. Expression of colicin genes is regulated by the DNA-damage SOS
95 response, but it can also be influenced by other global regulatory networks [28]. Colicin
96 production leads to the death of the producing cell and they are lethal for close-related
97 strains which are recognized by the bacteriocin, being the producer strain immune to them.

98 All colicins share as to their mode of action common steps that involve recognition of their
99 cognate receptors in the outer membrane of target cells, translocation across the outer
100 membrane, and activation of their toxic effect. A great variety of killing mechanisms have
101 been described such as membrane pore formation (e.g. colicin A), DNA nuclease activity
102 (colicin E2), and inhibition of the biosynthesis of proteins (colicins E3, E5, D),
103 peptidoglycan, and the lipopolysaccharide O-antigen (colicin M) [5, 24, 28, 54, 113].

104 By contrast, microcins are smaller (<10 kDa), they are not lethal against the producing cell
105 and their regulation is SOS-independent. Gene clusters are located either in plasmids or in
106 the chromosome and consist of structural and immunity genes and those coding for
107 transport or modification enzymes [95]. Two main sub-classes, I and II, have been
108 established depending on their post-translational modifications, gene cluster organization

and the sequence of the leader peptide, showing great structural heterogeneity [24, 42, 54]. Their synthesis is activated under specific stress conditions and, once synthesized, they are actively transported outside the cell either by microcin-specific or general transporters. Some microcins recognize specific receptors in the target cell, usually involved in uptaking essential nutrients. Others are synthesized as harmless peptides which are further processed and activated within the target cell [43]. Their killing mechanism is not fully understood but, in some cases, disruption of the cell membrane polarity [79], transcription inhibition by binding to RNA polymerases [39] or translation inhibition [93] have been documented. On the other hand, bacteriocins produced by Gram-positive bacteria are usually small, heat-stable cationic peptides with high isoelectric points. They are active preferably against a wide panel of Gram-positive microorganisms, including food-borne and spoilage bacteria. This feature has been the main driving force of bacteriocin research, particularly of those produced by the food-related lactic acid bacteria as for their use as natural preservatives in food [33, 46]. Bacteriocin gene clusters can be plasmid- or chromosomally-encoded, and some are localized in transposons, as described for nisin [65]. The gene clusters basically consist of the structural gene and those involved in immunity. Genes specifying modification enzymes are also present in some cases. Moreover, Gram-positive microorganisms have evolved specific regulation mechanisms related to bacteriocin synthesis and transport [61, 76, 113]. Owing to the great variety of chemical and structural properties of bacteriocins, several classification schemes have been proposed based on different criteria such as molecular weight, producing microorganism, structure or mode of action, although it still remains controversial and a universal classification is an issue for on-going discussions [36, 73, 97,

110]. The classification proposed by Heng and Tagg [62] integrates bacteriocins produced by both Gram-positive and Gram-negative bacteria and establishes four main classes. Class I or lantibiotics encompasses small (<15 kDa), heat-stable, post-translational-modified peptides containing amino acids such as lanthionine, β -methyl-lanthionine and dehydrated amino acids, which form distinctive intramolecular structural rings. Class I is sub-classified in 3 sub-classes: the linear I-a, represented by cationic and pore-forming peptides; the globular I-b, non-cationic peptides which inhibit enzymatic reactions; and the multi-component I-c, composed by two peptides, both needed to be fully active. Class II bacteriocins are defined as small (<15 kDa), heat-stable, and non-post-translational-modified, usually amphiphilic and/or hydrophobic. They are sub-classified into three sub-classes: Pediocin-like II-a, characterized by a conserved N-terminal sequence YGNGV/L and a stabilizing disulfide bond, highly active against *Listeria* and other genera such as *Enterococcus*, *Lactobacillus*, *Pediococcus* or *Clostridium*, among others; sub-class II-b represents a miscellaneous group of linear non-pediocin-like peptides; and sub-class II-c comprises multi-component bacteriocins. Another group, class III, is composed by large (>30 kDa) heat-labile proteins, which are sub-divided into sub-class III-a or bacteriolytic proteins, and sub-class III-b or non-lytic, which are generally active on cytosolic targets. Finally, class IV includes circular proteins characterized by a head-to-tail covalent bond. Examples of cell wall-active bacteriocins are shown in Table 1.

The bacterial cell wall

The cell wall represents the first barrier between the bacterial cells and their environment. It preserves the integrity of the cell by maintaining a defined and stable cell shape; it is

needed to counteract the inner osmotic pressure and represents an assembly scaffold for other surface macrostructures such as polysaccharides, S-layers, flagella and secretion systems [64, 124]. Moreover, the cell wall is a dynamic structure that participates also in cell growth and cell division [108, 142]. This structure is, therefore, crucial for survival and as such it is targeted by several antibiotics, bacteriophages and bacteriocins.

The bacterial cell wall is composed basically by peptidoglycan (PG), anionic polymers, proteins, and polysaccharides. The PG structure is formed by a network of linear glycan strands made up of alternating *N*-acetylglucosamine (NAG) and *N*-acetylmuramic acid (NAM) covalently linked by β 1-4 glycosidic bonds. Linked to NAM, there is a pentapeptide chain L-Ala-D-Glu-X-D-Ala-D-Ala, where X represents a diamino acid, usually a *meso*-diaminopimelic acid (DAP) in most Gram-negative or L-Lys in Gram-positive bacteria. The glycan strands are further cross-linked via the pentapeptide either directly or through a short peptide bridge, depending on the species. Since the peptides are localized helically along the sugar strand, cross-links are made in all directions, forming a multilayered three-dimensional network [116].

PG is present in all bacteria, except in Mycoplasmas, Planctomyces and the genera *Rickettsia* and *Chlamidiae* [140]. A scheme of the CW structure of Gram-positive and Gram-negative bacteria is shown in Fig. 1. In Gram-positive bacteria, the PG represents the 90 % of the total cell wall. Anionic polymers such as teichoic acids (or lipoteichoic acids when anchored to the cytoplasmic membrane) are also major constituents. Proteins can be either covalently-linked to PG or associated through cell wall-binding domains. In Gram-negative microorganisms, the PG is a thin layer that accounts only for the 10 % of the CW, being the external membrane the outermost structure. The lipopolysaccharide (LPS) is the

major constituent that contributes to the structural integrity of the cell and acts as a protective barrier.

The biosynthesis of PG is a multistage process beginning in the cytoplasm where the UDP-NAG and UDP-NAM-pentapeptide units are synthesized. Still in the cytoplasm but on the membrane side, lipid I is synthesized by the addition of the UDP-NAM-pentapeptide unit to the lipid carrier undecaprenyl-phosphate. Subsequently, UDP-NAG is transferred to lipid I, yielding lipid II [137]. The PG monomer is translocated through the membrane and, once in the periplasm, it is polymerized into the growing PG chain by the Penicillin-Binding-Proteins (PBPs), with glycosyltransferase and/or transpeptidase activities [122]. The lipid carrier is recycled to be used in a new cycle of PG synthesis.

Despite the fact that the basic chemical architecture of the PG is similar in bacteria, no species keeps its PG in an unmodified state and may vary even within the same species depending on growth conditions [139]. Modification of the PG may occur along synthesis and maturation (e.g. degree of cross-linking) but also by the activity of particular enzymes, very often involved in resistance to antimicrobials. This is the case of PG O-acetylation accounting for resistance to lysozyme [8, 31, 50] or the presence of D-lactate, D-Ser or Gly instead of D-Ala in the last position of the pentapeptide in some vancomycin resistant bacteria [112].

Lipid II-binding bacteriocins

Several antibiotics are known to target the different steps of cell wall biosynthesis. Particularly, the cell wall precursor lipid II is very often targeted and different recognition domains for several antibiotics have been described [18, 129]. Moreover, it has been

recently described that some defensins, antimicrobial peptides produced by animals, plants and fungi, also target lipid II to exert their antibacterial activity [126, 128]. In the case of bacteriocins, many have been described to bind to lipid II, including pore- and non-pore forming lantibiotics, non modified bacteriocins, two-peptide bacteriocins and some Gram-negative colicins (Fig. 2). In particular examples, potent inhibitory activities comparable to leading antibiotics such as vancomycin have been described [69].

Nisin and nisin-like bacteriocins

The lantibiotic nisin A is the most studied Gram-positive bacteriocin. It is a 3.3 kDa, elongated, amphiphilic and positively-charged peptide with a wide spectrum of activity, inhibiting several Gram-positive and also some Gram-negative bacteria, provided that the external membrane is disrupted [133]. Several natural nisin variants, produced by *Lactococcus lactis* (nisin A, Z, F and Q) and by *Streptococcus uberis* (nisin U), have been isolated. Early work on the mode of action of nisin already suggested that cell wall biosynthesis was inhibited [111] and, later on, it was experimentally confirmed that nisin makes use of lipid II as a docking molecule for pore formation [19, 23]. Lipid II is an integral part of the pore which is made up of 8 molecules of nisin and 4 of lipid II [59]. The combination of both, inhibition of cell wall biosynthesis and pore formation, is the basis of the potent activity of nisin. Binding to lipid II also implies that the cell wall precursor is delocalized from the sites where is needed for cell wall biosynthesis, interfering with cell growth and cell division [60, 68]. Moreover, binding to lipid II is also needed for effective membrane disruption in germinated spores to inhibit spore outgrowth from several pathogenic Gram-positive bacteria [56, 90]. Nisin has also been reported to activate cell

wall hydrolytic enzymes, particularly in staphylococci at the septum level, by displacing them from the teichoic and lipoteichoic acids [12, 13].

The N-terminus of nisin, specifically rings A and B, forms an essential binding cage which interacts with the pyrophosphate moiety of lipid II via hydrogen bonds [67] and the C-terminus is essential for pore formation [145]. Their contribution to bacterial killing has been assessed by using mutated nisin versions [145]. Interestingly, specific mutations on the hinge region resulted in nisin variants with enhanced activity [45].

The nisin-like lipid II-binding structural motif is present in many pore-forming lantibiotics such as gallidermin and epidermin [15], mutacin 1140 [132], subtilin [105] and bovicin HC5 [104], whose interaction with lipid II has been experimentally demonstrated. Of note, the pore forming ability of these nisin-like lipid II-binding peptides seems to be strongly dependent on membrane thickness and composition and determines the inhibitory spectra of these lantibiotics. Thereby, in order to evaluate the contribution of pore formation to the mode of action of these and other bacteriocins, special care must be taken when choosing a particular susceptible strain [138].

Mersacidin and mersacidin-like lantibiotics

Mersacidin is a small 1.8 kDa globular uncharged lantibiotic produced by *Bacillus* HIL Y-84,54728 [30]. It is active against a variety of Gram-positive bacteria and, remarkably, against methicillin-resistant *S*t*a*p*h**y**l**o**c**c**o**c**c**u**s* *a*u*r**e**u**s* (MRSA) with comparatively higher activity than vancomycin in animal models [30, 74, 98]. Mersacidin is not a pore-forming bacteriocin. Instead, it strongly inhibits the transglycosilation step during cell wall biosynthesis by binding to lipid II without affecting the biosynthesis of DNA, RNA or

247 proteins [21, 22]. The structure of the complex mersacidin-lipid II has not been solved.
248 However, NMR analyses revealed that mersacidin possesses a dynamic conformation able
249 to suffer structural changes depending on the environmental conditions, thus modulating
250 the distribution of the charged residues, which affects the effective interaction with lipid II
251 [66]. Moreover, mersacidin activity is enhanced by calcium ions *in vivo*, promoting its
252 interaction with the negatively charged surface of the cytoplasmic membrane [16].
253 Mersacidin and related lantibiotics are characterized by the presence of an intertwined
254 tioether bridge within the conserved TxS/TxE/DC motif, being the glutamate residue
255 essential for the inhibitory activity, as shown by site-directed mutagenesis [134]. This
256 pattern is conserved in other lantibiotics indicating a putative inhibitory activity of these
257 bacteriocins based on lipid II-binding [14].
258 Among mersacidin-like lantibiotics, inhibition of cell wall biosynthesis has been
259 demonstrated for plantaricin C and nukacin ISK-1 [70, 143]. Moreover, the lantibiotic
260 planosporicin was discovered during a screening for inhibitors of peptidoglycan inhibitors
261 [29]. There are several lantibiotics whose structure resembles that of plantaricin C and
262 nukacin ISK-1 (i.e. the lacticin 481 group). They all have their particular inhibitory spectra
263 and their activity could rely also on lipid II-binding and pore formation [7, 14, 41].
264 Plantaricin C is a 3.5 kDa bacteriocin, synthesized by *Lactobacillus plantarum* LL441,
265 which displays inhibitory activity against a wide range of Gram-positive bacteria, including
266 food-borne pathogens, such as *Staphylococcus*, *Streptococcus*, *Clostridium* or *Bacillus* [52].
267 It shares structural features with nisin and mersacidin; it has a highly positively-charged N-
268 terminus, which may facilitate the interaction with the negatively charged cytoplasmic
269 membrane, and a ring and compact conformation in the C-terminus, resembling the

mersacidin lipid II-binding motif [136]. Accordingly, plantaricin C is able to form pores in model membranes and intact cells of particular bacterial species but it is also a potent inhibitor of cell wall biosynthesis forming a tighter complex with lipid II when compared to mersacidin [53, 143].

Nukacin ISK-1 is a 2.9 kDa lantibiotic produced by *Staphylococcus warneri* ISK-1 with a N-terminal linear domain and a globular C-terminus, essential for the antimicrobial activity, which holds the mersacidin-like lipid II-binding motif TxS/TxD/EC [71, 121]. Nukacin ISK-1 is bacteriostatic and unable to form pores. Instead, it binds to lipidII leading to the accumulation of cell wall precursors inside the cell. Treated cells show a reduced thickness of the cell wall and incomplete septa [2]. Immunity has been associated with the cooperative role of the ABC transporter NukFEG and the lantibiotic-binding immunity protein NukH, which may block the bacteriocin before reaching its target [101].

Two-peptide lantibiotics

A growing class of lipid II-binding molecules is constituted by two-peptide lantibiotics or class Ic according to the Heng and Tagg's classification [62]. In these systems, two pre-peptides are ribosomally-synthesized as inactive forms (LanA1 and LanA2) which are later enzymatically-modified into their mature forms, the α -peptide carrying a mersacidin-like lipid II domain and an elongate positively-charged β -peptide involved in pore formation. Both peptides are encoded by their corresponding structural genes, act synergistically usually in a 1:1 ratio, and are required for full activity. This distribution of specialized killing mechanisms in two peptides has been described for lacticin 3147 [144] and haloduracin [102] and may hold true for other closely related two-peptide lantibiotics [99].

Lacticin 3147 is synthesized by *L. lactis* ssp. *lactis* DPC3147 and it is highly active against Gram-positive bacteria, including food-borne pathogens such as *Listeria monocytogenes* and *Bacillus cereus* or relevant pathogens such as MRSA [91, 119, 120]. Lacticin 3147 structure was resolved by Martin et al [83] and it is composed by LtnA1 (3.3 kDa), the globular-type lantibiotic with a mersacidin-like lipid II-binding motif, and LtnA2 (2.8 kDa), a positively-charged elongated-type lantibiotic. Both peptides are needed for high inhibitory activity at nanomolar concentration [96, 144]. LtnA1 has been shown to be a strong inhibitor of cell wall biosynthesis in *in vitro* assays. The interaction with lipid II appears to stabilize LtnA1 promoting its interaction with LtnA2, capable of pore formation [91, 144]. Potassium release assays showed that LtnA1 should be present before the final action of LtnA2, demonstrating that LtnA1 and LtnA2 act in a sequential manner in a 1:1 ratio, an event which has been frequently found for other two-peptide bacteriocins [96 and references therein]. Mutagenesis assays showed that the rings of LtnA1 involved in lipid II-binding, the glutamate residue in this region, as well as the rings in LtnA2 involved in the interaction of the two peptides, are essential for activity [35]. In addition to this, the presence of calcium ions, or in general a positively-charged environment, was proved to enhance the antimicrobial activity of lacticin 3147 as LtnA1 binds to whole cells only when it is surrounded by positive charges, either calcium or the positively-charged partner LtnA2 [16]. It is worth-noting that the inhibitory activity is also strain-dependent [96].

Haloduracin is produced by the alkaliphilic *Bacillus halodurans* C-125 and have inhibitory activity against several Gram-positive bacteria and also inhibits spore outgrowth of *Bacillus anthracis* [80], being its effectiveness strain-dependent [103]. It is composed of two lantibiotic-type peptides, Hala (2.8 kDa) and Hal β (2.3 kDa) [92], which act synergistically

at a nanomolar concentration. Hal α contains several overlapping rings and the lipid II-binding motif present in mersacidin, actagardine and LtnA of lacticin 3147, while Hal β shows a more elongated structure. Hal α binds to lipid II and inhibits transglycosilation by PBP1 during PG biosynthesis. This complex promotes binding of Hal β that forms pores in the membrane [102]. This sequential mechanism of action, suggested to occur in a lipidII:Hal α :Hal β (1:2:2) ratio, is similar to that of lacticin 3147 despite having significant structural differences [102, 103].

Lactococcin 972

Lactococcin 972 (Lcn972) is a 7.5 kDa, cationic and highly active bacteriocin synthesized by *Lactococcus lactis* IPLA972. So far, it is the first non-lantibiotic that does not target the cytoplasmic membrane, i.e. it does not make pores [86]. Rather, it inhibits PG biosynthesis by binding specifically to lipid II. Lcn972 activity was antagonized *in vivo* by lipid II, and not by other cell wall precursors. Lcn972 also co-precipitated with micelles containing lipid II, and interfered *in vitro* with the enzymatic reactions of PBP2 (polymerization of PG) and FemX, both enzymes that use lipid II as a substrate [84]. In contrast to other lipid II-binding bacteriocins, Lcn972 shows two particular features: first, it seems to block the incorporation of cell wall precursors at the septum; and second, it possesses a narrow activity spectrum, being active exclusively against lactococci under active division [85]. The existence of a putative co-target has been proposed to explain this targeted mode of action.

Another striking feature is that Lcn972 is easily inactivated by heat, anticipating a complex structure-function relationship. Lcn972 was claimed to be a homodimer based on the results

of in-gel bioassays in which the inhibitory activity appeared to be linked to a 15 kDa band, instead of the expected 7.5 kDa [86]. However, recent experimental data revealed that this aberrant migration occurred only in the presence of glycerol that stabilizes the folded form of Lcn972 and preliminary NMR data further discard the presence of such a homodimer [Turner D., personal communication].

The lack of homology between Lcn972 and other lipid II-binding peptides suggests that Lcn972 carries a novel lipid II-binding motif. Interestingly, there are more than 100 hits in the public databases that are related to Lcn972, building the protein family Pfam09683.

Colicin M

Within Gram-negative bacteriocins, colicin M, a 29.5 kDa protein synthesized by *E. coli*, is a unique colicin that interferes with the biosynthesis of PG and the O-antigen of the LPS in susceptible *E. coli* strains [57, 58, 123]. Colicin M is imported in susceptible cells by recognizing the ferrichrome receptor FhuA, and subsequently energy-dependent translocated into the periplasm to exert its antimicrobial activity [17, 130]. Its narrow activity spectrum is due to the species-specific condition of the receptors and the translocation mechanisms involved. It has a phosphoesterase activity which degrades lipid II, specifically cleaving the phosphodiester bond between the lipid moiety and the pyrophosphoril group [44, 57], in a magnesium-dependent manner [4]. Consequently, the lipid carrier C-55 cannot be recycled in new PG synthesis rounds nor in the synthesis of the O-antigen. Interestingly, Patin et al [106] have demonstrated that colicin M can hydrolyze *in vitro* and *in vivo* any lipid II molecule regardless the composition of the peptide side chain, thus representing a good candidate to study cell wall degradation in bacteria.

The structure of colicin M revealed a complex folded conformation challenging the identification of the typical colicin domains [147]. However, the high identity observed in the C-terminus of colicin M and other orthologs in several species of *Burkholderia*, *Pectobacterium*, and virulent *Pseudomonas*, supports the notion that the catalytic domain resides in this region, while the N-terminus and the central region are likely involved in target receptor recognition and translocation, respectively [5, 109, 147].

Cell wall-degrading bacteriocins

Several large and heat-sensitive proteins synthesized by bacteria that hydrolyze the cell wall have been described. They are comprised into class IIIa (so-called bacteriolysins), although their classification as bacteriocins is controversial [36, 62]. Bacteriolysins are usually organized in modules bearing catalytic activities and target recognition domains, resembling those present in bacteriophage endolysins [63], and streptococcal fratricins [9]. Immunity proteins are encoded in the vicinity of the structural genes and they often encode FemABX-like proteins, peptidyl transferases that catalyze the incorporation of amino acid(s) into the interchain peptide bridge of the PG [11, 48]. Examples of class IIIa bacteriolysins are listed in Table 1 and some examples are given below.

Lysostaphin

Lysostaphin may be the most studied bacteriolytic bacteriocin with regard to clinical applications. It is a 27 kDa metallo-enzyme firstly identified in *Staphylococcus simulans* [125] and highly specific against *Staphylococcus aureus* [3, 55]. Its mature form displays an N-terminal domain responsible for the catalytic activity, and a C-terminal involved in

binding to the target PG [3]. Lysostaphin is a glycylglycine endopeptidase targeting the pentaglycine cross-bridge of the PG in many staphylococci [55], cleaving specifically between the third and the fourth Gly residues [127]. Producer strains do not have specific immunity genes; instead, they are resistant due to the plasmid-encoded gene *lif*, involved in the addition of serine residues to the pentaglycine bridge that prevents hydrolysis by lysostaphin [38, 135]. Several authors have proposed lysostaphin as an effective therapeutic agent against *S. aureus* or as a tool to detect this pathogen in food matrices [77 and references therein].

Zoocin A

Zoocin A is a 30 kDa endopeptidase synthesized by *Streptococcus equi* subsp. *zooepidemicus* 4881 that hydrolyzes the bond between the terminal D-alanine of the peptide side chain and the L-alanine of the cross bridge in the PG of sensitive streptococci [49]. It carries two functional domains: the catalytic N-terminus, showing high similarity to other PG endopeptidases such as lysostaphin, and the C-terminal domain involved in PG recognition and binding [1]. Immunity relies on *zif*, involved in the addition of alanine residues to the cross bridge, making it longer and more resistant to hydrolysis. Zif shows high similarity with FemABX-like proteins [48, 117].

Millericin B

Millericin B is a 28 kDa PG hydrolase synthesized by *Streptococcus milleri* NMSCC 061 with inhibitory activity against a wide range of Gram-positive bacteria. Its endopeptidase activity cleaves both at the peptide side chain and the cross bridge [10]. Beukes and

Hastings [11] have identified three genes putatively involved in immunity and export. *milF* and *tRNA^{Leu}* incorporate leucine residues into the cross bridge that hinder hydrolysis. *milT* is homologous to ABC transporters and is likely involved in millericin export.

Pesticin

Within Gram-negatives, PG hydrolytic enzymes are also found. For example, pesticin is a 39.9 kDa bacteriocin synthesized by *Yersinia pestis* which kills other *Yersinia* species and some *E. coli* strains [28]. The genetic organization and its three-domain structural architecture resemble that of colicins featuring an N-terminal translocation domain, a central receptor binding domain, and the C-terminal activity domain. The activity domain has a similar folding to lysozyme-related proteins such as the archetypal phage T4 lysin [107]. Although they differ in sequence, both T4 lysozyme and pesticin share the same enzymatic activity, cleaving the β 1-4 glycosidic bond between NAM and NAG in the PG chain [141]. Like colicin M, pesticin's receptor is the outer membrane iron-siderophore transporter FyuA which also plays a role as virulent factor of many pathogens. Immunity to pesticin relies on Pim, a protein which specifically recognizes a sequence located in the catalytic domain.

The modular organization of pesticin allowed designing a hybrid bacteriocin composed by the FyuA-receptor domain and a foreign phage-related muramidase domain, not recognized by the immunity protein Pim. This hybrid bacteriocin is able to penetrate across the outer membrane and effectively kill pesticin producers and several Gram-negative bacteria [82].

Cell wall-active bacteriocins as biotechnological tools

Bacteriocins have mainly been considered as food biopreservatives, particularly those produced by lactic acid bacteria (LAB). In fact, more than 700 patents related to LAB bacteriocins have been registered and more than 400 are linked to the improvement of food quality, probiotics for animal feed, and mastitis treatment [46, 94]. The potential of LAB bacteriocins in food biopreservation relies basically on the traditional role of these bacteria as starters in food fermentations and their GRAS (Generally Regarded As Safe) status. Moreover, the bacteriocins they produce do not have a toxic effect on eukaryotic cells [46, 82] and they have a wider spectrum of activity compared to those produced by Gram-negative bacteria, impairing the development of food-borne pathogens. Accordingly, several LAB bacteriocins are commercialized in several countries as food biopreservatives. Their application as biopreservatives in food has been extensively reviewed elsewhere [46, 47, 94, 97].

From a clinical point of view, the development of pathogens such as vancomycin-resistant enterococci (VRE) and MRSA is of particular concern to animal and public health agencies worldwide. In this line, bacteriocins such as nisin, lacticin 3147, mersacidin or lysostaphin have also been considered as an alternative to traditional antibiotics [6, 37, 74, 75, 131].

Besides the applications of bacteriocins based on their antibiotic activities, cell wall-active bacteriocins may be also very useful to study cell wall biology and, particularly, the response to cell envelope stress in relevant microorganisms. As outlined below, this approach has been exemplified by the role of the cell-wall active bacteriocin Lcn972 in understanding the molecular mechanisms that govern the response of the industrially

relevant *L. lactis* to cell wall damaging. The generated knowledge has provided a basis for improving *L. lactis* performance in food fermentations (Fig. 3).

L. lactis is the main component of the mesophilic starter cultures used in cheese manufacturing and robust strains are continuously demanded to improve the yield of industrial fermentations and guarantee the optimal characteristics of the final fermented product [20]. In the dairy environment, *L. lactis* must tolerate diverse stress conditions either during starter manufacture or along the fermentation process. Thus, the knowledge on how *L. lactis* monitors cell wall integrity and develops appropriate responses is, without a doubt, relevant to optimize its performance and robustness. In this context, the transcriptional response of *L. lactis* to Lcn972 helped to identify CesSR as the main two component system (TCS) that orchestrates the primary line of defense to cell wall damage in this microorganism [87]. Several genes in *L. lactis* were identified as members of the CesR regulon and among them, *llmg0169* and the operon *llmg2164-2163*, encoding a putative membrane protein and a Psp-like protein, respectively, were highly induced. These genes could be further correlated to a higher survival of *L. lactis* under technological stress such as low pH, heat, or NaCl, among others, and have been proposed as biomarkers for strain robustness [114] (Fig. 3).

The characterization of resistant mutants to cell wall-active bacteriocins of industrially relevant microorganisms may also help to select more robust strains and reveal interesting mechanisms by which they become better adapted to their industrial use. For instance, a recent work has shown that *L. lactis* is able to shorten the peptide chain of its muropeptides to counteract the activity of Lcn972. Remarkably these mutants were also insensitive to

other dairy preservatives such as lysozyme and nisin, and to some bacteriophages which are a major threat in dairy fermentations [115].

There are as well examples of biotechnological applications derived from the current knowledge on cell wall-active bacteriocins. CesSR and its orthologues in other Gram-positives such as LiaSR in *B. subtilis* and VraSR in *S. aureus* were shown to be specifically induced by lipid II-binders such as nisin, bacitracin and vancomycin [78, 87, 88]. This feature has been further exploited to develop HTS (High-Throughput Screening) reporter systems to identify cell wall active compounds and monitor the stress response they trigger. These methods were designed with the aim to be easy-handling, quick and applicable to high amount of samples. A reporter *B. subtilis* strain was created by fusing the promoter of the TCS LiaSR to the *lacZ* gene, thus expressing beta-galactosidase as response to antibiotics interfering with the lipid II cycle [89]. Qualitative assays were performed with agar-diffusion-tests and quantification was possible in liquid cultures in microtiter plates, thus, enabling to screen and identify lipid II-interfering compounds [26]. Similarly, the promoter of *llmg0169*, the most up-regulated gene after CesSR activation in *L. lactis*, was fused to the gene encoding the green fluorescence protein (GFP) and a microtiter fluorescence-based assay was developed to monitor cell envelope response in *L. lactis* under specific conditions [27].

In view of these highlighted reports, cell wall-active bacteriocins are envisaged, not only as effective antimicrobials, but also as tools to get a deeper knowledge on the genetic and physiological consequences of cell wall damage in bacteria. Understanding bacterial

regulatory mechanisms involved in stress responses may ultimately lead to a rational selection of industrially relevant microorganisms for specific applications.

Acknowledgements

Work at DairySafe group has been funded by grants BIO2004-04312, BIO2006-65061, BIO2010-17414 of the Ministerio de Economía y Competitividad (Spain) and grants EQUIP08-01 and COF08-01 from FICYT (Asturias, Spain). C.R. is a recipient of a predoctoral JAE-CSIC fellowship.

References

1. Akesson M, Dufour M, Sloan GL, Simmonds RS (2007) Targeting of streptococci by zoocin A. FEMS Microbiol Lett 270 (1):155-161
2. Asaduzzaman SM, Nagao J, Iida H, Zendo T, Nakayama J, Sonomoto K (2009) Nukacin ISK-1, a bacteriostatic lantibiotic. Antimicrob Agents Chemother 53 (8):3595-3598
3. Baba T, Schneewind O (1996) Target cell specificity of a bacteriocin molecule: a C-terminal signal directs lysostaphin to the cell wall of *Staphylococcus aureus*. EMBO J 15 (18):4789-4797
4. Barreteau H, Bouhss A, Fourgeaud M, Mainardi JL, Touzé T, Gérard F, Blanot D, Arthur M, Mengin-Lecreulx D (2009) Human- and plant-pathogenic *Pseudomonas* species produce bacteriocins exhibiting colicin M-like hydrolase activity towards peptidoglycan precursors. J Bacteriol 191 (11):3657-3664
5. Barreteau H, El Ghachi M, Barneoud-Arnoulet A, Sacco E, Touzé T, Duché D, Gérard F, Brooks M, Patin D, Bouhss A, Blanot D, van Tilbeurgh H, Arthur M, Lloubès R, Mengin-Lecreulx D (2012) Characterization of Colicin M and its Orthologs Targeting Bacterial Cell Wall Peptidoglycan Biosynthesis. Microb Drug Resist. doi:10.1089/mdr.2011.0230
6. Bastos MCF, Coutinho BG, Coelho MLV (2010) Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications. Pharmaceuticals 3 (4):1139-1161
7. Bauer R, Dicks LM (2005) Mode of action of lipid II-targeting lantibiotics. Int J Food Microbiol 101 (2):201-216
8. Bera A, Herbert S, Jakob A, Vollmer W, Götz F (2005) Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is

- 529 the major determinant for lysozyme resistance of *Staphylococcus aureus*. Mol
530 Microbiol 55 (3):778-787
- 531 9. Berg KH, Biørnstad TJ, Johnsborg O, Håvarstein LS (2012) Properties and biological
532 role of streptococcal fratricins. Appl Environ Microbiol 78 (10):3515-3522
- 533 10. Beukes M, Bierbaum G, Sahl HG, Hastings JW (2000) Purification and partial
534 characterization of a murein hydrolase, millericin B, produced by *Streptococcus*
535 *milleri* NMSCC 061. Appl Environ Microbiol 66 (1):23-28
- 536 11. Beukes M, Hastings JW (2001) Self-protection against cell wall hydrolysis in
537 *Streptococcus milleri* NMSCC 061 and analysis of the millericin B operon. Appl
538 Environ Microbiol 67 (9):3888-3896
- 539 12. Bierbaum G, Sahl HG (1985) Induction of autolysis of staphylococci by the basic
540 peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic
541 enzymes. Arch Microbiol 141 (3):249-254
- 542 13. Bierbaum G, Sahl HG (1987) Autolytic system of *Staphylococcus simulans* 22:
543 influence of cationic peptides on activity of N-acetylmuramoyl-L-alanine amidase. J
544 Bacteriol 169 (12):5452-5458
- 545 14. Bierbaum G, Sahl HG (2009) Lantibiotics: mode of action, biosynthesis and
546 bioengineering. Curr Pharm Biotechnol 10 (1):2-18
- 547 15. Bonelli RR, Schneider T, Sahl HG, Wiedemann I (2006) Insights into in vivo activities
548 of lantibiotics from gallidermin and epidermin mode-of-action studies. Antimicrob
549 Agents Chemother 50 (4):1449-1457

- 550 16. Böttiger T, Schneider T, Martínez B, Sahl HG, Wiedemann I (2009) Influence of
551 Ca(2+) ions on the activity of lantibiotics containing a mersacidin-like lipid II binding
552 motif. *Appl Environ Microbiol* 75 (13):4427-4434
- 553 17. Braun V, Patzer SI, Hantke K (2002) Ton-dependent colicins and microcins: modular
554 design and evolution. *Biochimie* 84 (5-6):365-380
- 555 18. Breukink E, de Kruijff B (2006) Lipid II as a target for antibiotics. *Nat Rev Drug*
556 *Discov* 5 (4):321-332
- 557 19. Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl H, de Kruijff B (1999) Use
558 of the cell wall precursor lipid II by a pore-forming peptide antibiotic. *Science* 286
559 (5448):2361-2364
- 560 20. Bron PA, Kleerebezem M (2011) Engineering lactic acid bacteria for increased
561 industrial functionality. *Bioeng Bugs* 2 (2):80-87
- 562 21. Brötz H, Bierbaum G, Markus A, Molitor E, Sahl HG (1995) Mode of action of the
563 lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel
564 mechanism? *Antimicrob Agents Chemother* 39 (3):714-719
- 565 22. Brötz H, Bierbaum G, Reynolds PE, Sahl HG (1997) The lantibiotic mersacidin inhibits
566 peptidoglycan biosynthesis at the level of transglycosylation. *Eur J Biochem* 246
567 (1):193-199
- 568 23. Brötz H, Josten M, Wiedemann I, Schneider U, Götz F, Bierbaum G, Sahl HG (1998)
569 Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin,
570 epidermin and other lantibiotics. *Mol Microbiol* 30 (2):317-327

- 571 24. Budic M, Rijavec M, Petkovsek Z, Zgur-Bertok D (2011) *Escherichia coli* bacteriocins:
572 antimicrobial efficacy and prevalence among isolates from patients with bacteraemia.
573 PLoS One 6 (12):e28769. doi:10.1371/journal.pone.0028769
- 574 25. Bugg TD, Braddick D, Dowson CG, Roper DI (2011) Bacterial cell wall assembly: still
575 an attractive antibacterial target. Trends Biotechnol 29 (4):167-173
- 576 26. Burkard M, Stein T (2008) Microtiter plate bioassay to monitor the interference of
577 antibiotics with the lipid II cycle essential for peptidoglycan biosynthesis. J Microbiol
578 Methods 75 (1):70-74
- 579 27. Campelo AB, Rodríguez A, Martínez B (2010) Use of green fluorescent protein to
580 monitor cell envelope stress in *Lactococcus lactis*. Appl Environ Microbiol 76
581 (3):978-981
- 582 28. Cascales E, Buchanan SK, Duché D, Kleanthous C, Lloubès R, Postle K, Riley M,
583 Slatin S, Cavard D (2007) Colicin biology. Microbiol Mol Biol Rev 71 (1):158-229
- 584 29. Castiglione F, Cavaletti L, Losi D, Lazzarini A, Carrano L, Feroggio M, Ciciliato I,
585 Corti E, Candiani G, Marinelli F, Selva E (2007) A novel lantibiotic acting on
586 bacterial cell wall synthesis produced by the uncommon actinomycete
587 *Planomonospora* sp. Biochemistry 46 (20):5884-5895
- 588 30. Chatterjee S, Chatterjee DK, Jani RH, Blumbach J, Ganguli BN, Klesel N, Limbert M,
589 Seibert G (1992) Mersacidin, a new antibiotic from *Bacillus*. In vitro and in vivo
590 antibacterial activity. J Antibiot (Tokyo) 45 (6):839-845
- 591 31. Clarke AJ, Dupont C (1992) O-acetylated peptidoglycan: its occurrence,
592 pathobiological significance, and biosynthesis. Can J Microbiol 38 (2):85-91

- 593 32. Claverys JP, Martin B, Håvarstein LS (2007) Competence-induced fratricide in
594 streptococci. *Mol Microbiol* 64 (6):1423-1433
- 595 33. Cleveland J, Montville TJ, Nes IF, Chikindas ML (2001) Bacteriocins: safe, natural
596 antimicrobials for food preservation. *Int J Food Microbiol* 71 (1):1-20
- 597 34. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CG (2007) Bacteriocin
598 production as a mechanism for the antiinfective activity of *Lactobacillus salivarius*
599 UCC118. *Proc Natl Acad Sci U S A* 104 (18):7617-7621
- 600 35. Cotter PD, Deegan LH, Lawton EM, Draper LA, O'Connor PM, Hill C, Ross RP (2006)
601 Complete alanine scanning of the two-component lantibiotic lactacin 3147: generating
602 a blueprint for rational drug design. *Mol Microbiol* 62 (3):735-747
- 603 36. Cotter PD, Hill C, Ross RP (2005) Bacteriocins: developing innate immunity for food.
604 *Nat Rev Microbiol* 3 (10):777-788
- 605 37. Crispie F, Twomey D, Flynn J, Hill C, Ross P, Meaney W (2005) The lantibiotic
606 lactacin 3147 produced in a milk-based medium improves the efficacy of a bismuth-
607 based teat seal in cattle deliberately infected with *Staphylococcus aureus*. *J Dairy Res*
608 72 (2):159-167
- 609 38. DeHart HP, Heath HE, Heath LS, LeBlanc PA, Sloan GL (1995) The lysostaphin
610 endopeptidase resistance gene (*epr*) specifies modification of peptidoglycan cross
611 bridges in *Staphylococcus simulans* and *Staphylococcus aureus*. *Appl Environ*
612 *Microbiol* 61 (4):1475-1479
- 613 39. Delgado MA, Rintoul MR, Farías RN, Salomón RA (2001) *Escherichia coli* RNA
614 polymerase is the target of the cyclopeptide antibiotic microcin J25. *J Bacteriol* 183
615 (15):4543-4550

- 616 40. Diep DB, Skaugen M, Salehian Z, Holo H, Nes IF (2007) Common mechanisms of
617 target cell recognition and immunity for class II bacteriocins. *Proc Natl Acad Sci U S*
618 *A* 104 (7):2384-2389
- 619 41. Dufour A, Hindré T, Haras D, Le Pennec JP (2007) The biology of lantibiotics from the
620 lactacin 481 group is coming of age. *FEMS Microbiol Rev* 31 (2):134-167
- 621 42. Duquesne S, Destoumieux-Garzón D, Peduzzi J, Rebuffat S (2007) Microcins, gene-
622 encoded antibacterial peptides from enterobacteria. *Nat Prod Rep* 24 (4):708-734
- 623 43. Duquesne S, Petit V, Peduzzi J, Rebuffat S (2007) Structural and functional diversity of
624 microcins, gene-encoded antibacterial peptides from enterobacteria. *J Mol Microbiol*
625 *Biotechnol* 13 (4):200-209
- 626 44. El Ghachi M, Bouhss A, Barreteau H, Touzé T, Auger G, Blanot D, Mengin-Lecreulx
627 D (2006) Colicin M exerts its bacteriolytic effect via enzymatic degradation of
628 undecaprenyl phosphate-linked peptidoglycan precursors. *J Biol Chem* 281
629 (32):22761-22772
- 630 45. Field D, Connor PM, Cotter PD, Hill C, Ross RP (2008) The generation of nisin
631 variants with enhanced activity against specific gram-positive pathogens. *Mol*
632 *Microbiol* 69(1):218-230
- 633 46. Gálvez A, Abriouel H, López RL, Ben Omar N (2007) Bacteriocin-based strategies for
634 food biopreservation. *Int J Food Microbiol* 120 (1-2):51-70
- 635 47. García P, Martínez B, Rodríguez A, Rodríguez L (2010) Food biopreservation:
636 Promising strategies using bacteriocins, bacteriophages and endolysins. *Trends in*
637 *Food Science and Technology* 21:373-382

- 638 48. Gargis SR, Gargis AS, Heath HE, Heath LS, LeBlanc PA, Senn MM, Berger-Bächi B,
639 Simmonds RS, Sloan GL (2009) Zif, the zoocin A immunity factor, is a FemABX-like
640 immunity protein with a novel mode of action. *Appl Environ Microbiol* 75 (19):6205-
641 6210
- 642 49. Gargis SR, Heath HE, Heath LS, Leblanc PA, Simmonds RS, Abbott BD, Timkovich
643 R, Sloan GL (2009) Use of 4-sulfophenyl isothiocyanate labeling and mass
644 spectrometry to determine the site of action of the streptococcolytic peptidoglycan
645 hydrolase zoocin A. *Appl Environ Microbiol* 75 (1):72-77
- 646 50. Giaouris E, Briandet R, Meyrand M, Courtin P, Chapot-Chartier MP (2008) Variations
647 in the degree of D-Alanylation of teichoic acids in *Lactococcus lactis* alter resistance
648 to cationic antimicrobials but have no effect on bacterial surface hydrophobicity and
649 charge. *Appl Environ Microbiol* 74 (15):4764-4767
- 650 51. Gillor O, Riley MA, Chavan MA (2007) Bacteriocins' Role in Bacterial
651 Communication Bacteriocins. In: Springer Berlin Heidelberg, pp 135-145
- 652 52. González B, Arca P, Mayo B, Suárez JE (1994) Detection, purification, and partial
653 characterization of plantaricin C, a bacteriocin produced by a *Lactobacillus plantarum*
654 strain of dairy origin. *Appl Environ Microbiol* 60 (6):2158-2163
- 655 53. Gonzalez B, Glaasker E, Kunji E, Driessen A, Suarez JE, Konings WN (1996)
656 Bactericidal mode of action of plantaricin C. *Appl Environ Microbiol* 62 (8):2701-
657 2709
- 658 54. Gordon DM, O'Brien CL (2006) Bacteriocin diversity and the frequency of multiple
659 bacteriocin production in *Escherichia coli*. *Microbiology* 152 (Pt 11):3239-3244

660 55. Gründling A, Schneewind O (2006) Cross-linked peptidoglycan mediates lysostaphin
661 binding to the cell wall envelope of *Staphylococcus aureus*. J Bacteriol 188 (7):2463-
662 2472

663 56. Gut IM, Blanke SR, van der Donk WA (2011) Mechanism of inhibition of *Bacillus*
664 *anthracis* spore outgrowth by the lantibiotic nisin. ACS Chem Biol 6 (7):744-752

665 57. Harkness RE, Braun V (1989) Colicin M inhibits peptidoglycan biosynthesis by
666 interfering with lipid carrier recycling. J Biol Chem 264 (11):6177-6182

667 58. Harkness RE, Braun V (1989) Inhibition of lipopolysaccharide O-antigen synthesis by
668 colicin M. J Biol Chem 264 (25):14716-14722

669 59. Hasper HE, de Kruijff B, Breukink E (2004) Assembly and stability of nisin-lipid II
670 pores. Biochemistry 43 (36):11567-11575

671 60. Hasper HE, Kramer NE, Smith JL, Hillman JD, Zachariah C, Kuipers OP, de Kruijff B,
672 Breukink E (2006) An alternative bactericidal mechanism of action for lantibiotic
673 peptides that target lipid II. Science 313 (5793):1636-1637

674 61. Håvarstein LS, Diep DB, Nes IF (1995) A family of bacteriocin ABC transporters carry
675 out proteolytic processing of their substrates concomitant with export. Mol Microbiol
676 16 (2):229-240

677 62. Heng NCK, Tagg, J.R. (2006) What's in a name? Class distinction for bacteriocins. Nat
678 Rev Micro 4 (2)

679 63. Hermoso JA, García JL, García P (2007) Taking aim on bacterial pathogens: from
680 phage therapy to enzybiotics. Curr Opin Microbiol 10 (5):461-472

681 64. Höltje JV (1998) Growth of the stress-bearing and shape-maintaining murein sacculus
682 of *Escherichia coli*. Microbiol Mol Biol Rev 62 (1):181-203

- 683 65. Horn N, Swindell S, Dodd H, Gasson M (1991) Nisin biosynthesis genes are encoded
684 by a novel conjugative transposon. *Mol Gen Genet* 228 (1-2):129-135
- 685 66. Hsu ST, Breukink E, Bierbaum G, Sahl HG, de Kruijff B, Kaptein R, van Nuland NA,
686 Bonvin AM (2003) NMR study of mersacidin and lipid II interaction in
687 dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial
688 activity. *J Biol Chem* 278 (15):13110-13117
- 689 67. Hsu ST, Breukink E, Tischenko E, Lutters MA, de Kruijff B, Kaptein R, Bonvin AM,
690 van Nuland NA (2004) The nisin-lipid II complex reveals a pyrophosphate cage that
691 provides a blueprint for novel antibiotics. *Nat Struct Mol Biol* 11 (10):963-967
- 692 68. Hyde AJ, Parisot J, McNichol A, Bonev BB (2006) Nisin-induced changes in *Bacillus*
693 morphology suggest a paradigm of antibiotic action. *Proc Natl Acad Sci U S A* 103
694 (52):19896-19901
- 695 69. Iancu C, Grainger A, Field D, Cotter PD, Hill C, Ross, RP (2012) Comparison of the
696 Potency of the Lipid II Targeting Antimicrobials Nisin, Lacticin 3147 and
697 Vancomycin Against Gram-Positive Bacteria. *Probiotics and Antimicrobial Proteins*
698 4(2):116-121
- 699 70. Islam MR, Nishie M, Nagao J, Zendo T, Keller S, Nakayama J, Kohda D, Sahl HG,
700 Sonomoto K (2012) Ring A of nukacin ISK-1: a lipid II-binding motif for type-A(II)
701 lantibiotic. *J Am Chem Soc* 134 (8):3687-3690
- 702 71. Islam MR, Shioya K, Nagao J, Nishie M, Jikuya H, Zendo T, Nakayama J, Sonomoto K
703 (2009) Evaluation of essential and variable residues of nukacin ISK-1 by NNK
704 scanning. *Mol Microbiol* 72 (6):1438-1447

- 705 72. Kjos M, Borrero J, Opsata M, Birri DJ, Holo H, Cintas LM, Snipen L, Hernández PE,
706 Nes IF, Diep DB (2011) Target recognition, resistance, immunity and genome mining
707 of class II bacteriocins from Gram-positive bacteria. *Microbiology* 157 (Pt 12):3256-
708 3267
- 709 73. Klaenhammer TR (1988) Bacteriocins of lactic acid bacteria. *Biochimie* 70 (3):337-349
- 710 74. Kruszewska D, Sahl HG, Bierbaum G, Pag U, Hynes SO, Ljungh A (2004) Mersacidin
711 eradicates methicillin-resistant *Staphylococcus aureus* (MRSA) in a mouse rhinitis
712 model. *J Antimicrob Chemother* 54 (3):648-653
- 713 75. Kruszewska H, Zareba T, Tyski S (2004) Examination of antimicrobial activity of
714 selected non-antibiotic drugs. *Acta Pol Pharm* 61 Suppl:18-21
- 715 76. Kuipers OP, Beerthuizen MM, de Ruyter PG, Luesink EJ, de Vos WM (1995)
716 Autoregulation of nisin biosynthesis in *Lactococcus lactis* by signal transduction. *J*
717 *Biol Chem* 270 (45):27299-27304
- 718 77. Kumar JK (2008) Lysostaphin: an antistaphylococcal agent. *Appl Microbiol Biotechnol*
719 80 (4):555-561
- 720 78. Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K (2003) Two-
721 component system VraSR positively modulates the regulation of cell-wall
722 biosynthesis pathway in *Staphylococcus aureus*. *Mol Microbiol* 49 (3):807-821
- 723 79. Lagos R, Wilkens M, Vergara C, Cecchi X, Monasterio O (1993) Microcin E492 forms
724 ion channels in phospholipid bilayer membrane. *FEBS Lett* 321 (2-3):145-148
- 725 80. Lawton EM, Cotter PD, Hill C, Ross RP (2007) Identification of a novel two-peptide
726 lantibiotic, haloduracin, produced by the alkaliphile *Bacillus halodurans* C-125.
727 *FEMS Microbiol Lett* 267 (1):64-71

- 728 81. Lukacik P, Barnard TJ, Keller PW, Chaturvedi KS, Seddiki N, Fairman JW, Noinaj N,
729 Kirby TL, Henderson JP, Steven AC, Hinnebusch BJ, Buchanan SK (2012) Structural
730 engineering of a phage lysin that targets Gram-negative pathogens. *Proc Natl Acad*
731 *Sci U S A* 109 (25):9857-9862
- 732 82. Maher S, McClean S (2006) Investigation of the cytotoxicity of eukaryotic and
733 prokaryotic antimicrobial peptides in intestinal epithelial cells in vitro. *Biochem*
734 *Pharmacol* 71 (9):1289-1298
- 735 83. Martin NI, Sprules T, Carpenter MR, Cotter PD, Hill C, Ross RP, Vederas JC (2004)
736 Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic
737 activity. *Biochemistry* 43 (11):3049-3056
- 738 84. Martínez B, Böttiger T, Schneider T, Rodríguez A, Sahl HG, Wiedemann I (2008)
739 Specific interaction of the unmodified bacteriocin Lactococcin 972 with the cell wall
740 precursor lipid II. *Appl Environ Microbiol* 74 (15):4666-4670
- 741 85. Martínez B, Rodríguez A, Suárez JE (2000) Lactococcin 972, a bacteriocin that inhibits
742 septum formation in lactococci. *Microbiology* 146 (Pt 4):949-955
- 743 86. Martínez B, Suárez JE, Rodríguez A (1996) Lactococcin 972: a homodimeric
744 lactococcal bacteriocin whose primary target is not the plasma membrane.
745 *Microbiology* 142 (Pt 9):2393-2398
- 746 87. Martínez B, Zomer AL, Rodríguez A, Kok J, Kuipers OP (2007) Cell envelope stress
747 induced by the bacteriocin Lcn972 is sensed by the Lactococcal two-component
748 system CesSR. *Mol Microbiol* 64 (2):473-486

- 749 88. Mascher T, Margulis NG, Wang T, Ye RW, Helmann JD (2003) Cell wall stress
750 responses in *Bacillus subtilis*: the regulatory network of the bacitracin stimulon. Mol
751 Microbiol 50 (5):1591-1604
- 752 89. Mascher T, Zimmer SL, Smith TA, Helmann JD (2004) Antibiotic-inducible promoter
753 regulated by the cell envelope stress-sensing two-component system LiaRS of
754 *Bacillus subtilis*. Antimicrob Agents Chemother 48 (8):2888-2896
- 755 90. Mazzotta AS, Crandall AD, Montville TJ (1997) Nisin Resistance in *Clostridium*
756 *botulinum* Spores and Vegetative Cells. Appl Environ Microbiol 63 (7):2654-2659
- 757 91. McAuliffe O, Ryan MP, Ross RP, Hill C, Breeuwer P, Abee T (1998) Lacticin 3147, a
758 broad-spectrum bacteriocin which selectively dissipates the membrane potential. Appl
759 Environ Microbiol 64 (2):439-445
- 760 92. McClerren AL, Cooper LE, Quan C, Thomas PM, Kelleher NL, van der Donk WA
761 (2006) Discovery and in vitro biosynthesis of haloduracin, a two-component
762 lantibiotic. Proc Natl Acad Sci U S A 103 (46):17243-17248
- 763 93. Metlitskaya A, Kazakov T, Kommer A, Pavlova O, Praetorius-Ibba M, Ibba M,
764 Krasheninnikov I, Kolb V, Khmel I, Severinov K (2006) Aspartyl-tRNA synthetase is
765 the target of peptide nucleotide antibiotic Microcin C. J Biol Chem 281 (26):18033-
766 18042
- 767 94. Montalbán-López M, Sánchez-Hidalgo M, Valdivia E, Martínez-Bueno M, Maqueda M
768 (2011) Are bacteriocins underexploited? Novel applications for old antimicrobials.
769 Curr Pharm Biotechnol 12 (8):1205-1220
- 770 95. Moreno F, González-Pastor JE, Baquero MR, Bravo D (2002) The regulation of
771 microcin B, C and J operons. Biochimie 84 (5-6):521-529

- 772 96. Morgan SM, O'Connor P M, Cotter PD, Ross RP, Hill C (2005) Sequential actions of
773 the two component peptides of the lantibiotic lactacin 3147 explain its antimicrobial
774 activity at nanomolar concentrations. *Antimicrob Agents Chemother* 49 (7):2606-
775 2611
- 776 97. Nes IF, Diep DB, Holo H (2007) Bacteriocin diversity in *Streptococcus* and
777 *Enterococcus*. *J Bacteriol* 189 (4):1189-1198
- 778 98. Niu WW, Neu HC (1991) Activity of mersacidin, a novel peptide, compared with that
779 of vancomycin, teicoplanin, and daptomycin. *Antimicrob Agents Chemother* 35
780 (5):998-1000
- 781 99. O'Connor EB, Cotter PD, O'Connor P, O'Sullivan O, Tagg JR, Ross RP, Hill C (2007)
782 Relatedness between the two-component lantibiotics lactacin 3147 and staphylococcin
783 C55 based on structure, genetics and biological activity. *BMC Microbiol* 7:24
- 784 100. O'Connor EM, Shand RF (2002) Halocins and sulfolobocins: the emerging story of
785 archaeal protein and peptide antibiotics. *J Ind Microbiol Biotechnol* 28 (1):23-31
- 786 101. Okuda K, Aso Y, Nakayama J, Sonomoto K (2008) Cooperative transport between
787 NukFEG and NukH in immunity against the lantibiotic nukacin ISK-1 produced by
788 *Staphylococcus warneri* ISK-1. *J Bacteriol* 190 (1):356-362
- 789 102. Oman TJ, Lupoli TJ, Wang TS, Kahne D, Walker S, van der Donk WA (2011)
790 Haloduracin alpha binds the peptidoglycan precursor lipid II with 2:1 stoichiometry. *J*
791 *Am Chem Soc* 133 (44):17544-17547
- 792 103. Oman TJ, van der Donk WA (2009) Insights into the mode of action of the two-
793 peptide lantibiotic haloduracin. *ACS Chem Biol* 4 (10):865-874

- 794 104. Paiva AD, Breukink E, Mantovani HC (2011) Role of lipid II and membrane thickness
795 in the mechanism of action of the lantibiotic bovicin HC5. *Antimicrob Agents*
796 *Chemother* 55 (11):5284-5293
- 797 105. Parisot J, Carey S, Breukink E, Chan WC, Narbad A, Bonev B (2008) Molecular
798 mechanism of target recognition by subtilin, a class I lanthionine antibiotic.
799 *Antimicrob Agents Chemother* 52 (2):612-618
- 800 106. Patin D, Barreteau H, Auger G, Magnet S, Crouvoisier M, Bouhss A, Touzé T, Arthur
801 M, Mengin-Lecreulx D, Blanot D (2012) Colicin M hydrolyses branched lipids II
802 from Gram-positive bacteria. *Biochimie* 94 (4):985-990
- 803 107. Patzer SI, Albrecht R, Braun V, Zeth K (2012) Structural and mechanistic studies of
804 pesticin, a bacterial homolog of phage lysozymes. *J Biol Chem* 287 (28):23381-23396
- 805 108. Pérez-Núñez D, Briandet R, David B, Gautier C, Renault P, Hallet B, Hols P,
806 Carballido-López R, Guédon E (2011) A new morphogenesis pathway in bacteria:
807 unbalanced activity of cell wall synthesis machineries leads to coccus-to-rod transition
808 and filamentation in ovococci. *Mol Microbiol* 79 (3):759-771
- 809 109. Pilsl H, Glaser C, Gross P, Killmann H, Olschläger T, Braun V (1993) Domains of
810 colicin M involved in uptake and activity. *Mol Gen Genet* 240 (1):103-112
- 811 110. Rea MC, Ross RP, Cotter PD, Hill C, Drider D, Rebuffat S (2011) Classification of
812 Bacteriocins from Gram-Positive Bacteria. *Prokaryotic Antimicrobial Peptides*. In
813 Drider D, Rebuffat S: Springer New York, pp 29-53.
- 814 111. Reisinger P, Seidel H, Tschesche H, Hammes WP (1980) The effect of nisin on
815 murein synthesis. *Arch Microbiol* 127 (3):187-193

- 816 112. Reynolds PE, Courvalin P (2005) Vancomycin resistance in enterococci due to
817 synthesis of precursors terminating in D-alanyl-D-serine. *Antimicrob Agents*
818 *Chemother* 49 (1):21-25
- 819 113. Riley MA, Wertz JE (2002) Bacteriocins: evolution, ecology, and application. *Annu*
820 *Rev Microbiol* 56:117-137
- 821 114. Roces C, Campelo AB, Veiga P, Pinto JP, Rodríguez A, Martínez B (2009)
822 Contribution of the CesR-regulated genes *llmg0169* and *llmg2164-2163* to
823 *Lactococcus lactis* fitness. *Int J Food Microbiol* 133 (3):279-285
- 824 115. Roces C, Courtin P, Kulakauskas S, Rodríguez A, Chapot-Chartier MP, Martínez B
825 (2012) Isolation of *Lactococcus lactis* Mutants Simultaneously Resistant to the Cell
826 Wall-Active Bacteriocin Lcn972, Lysozyme, Nisin, and Bacteriophage c2. *Appl*
827 *Environ Microbiol* 78 (12):4157-4163
- 828 116. Rogers HJ, Perkins HR, Ward JB (1980) Microbial cell walls and membranes.
829 Chapman and Hall
- 830 117. Rohrer S, Berger-Bächi B (2003) FemABX peptidyl transferases: a link between
831 branched-chain cell wall peptide formation and beta-lactam resistance in gram-
832 positive cocci. *Antimicrob Agents Chemother* 47 (3):837-846
- 833 118. Ruiz-Barba JL, Cathcart DP, Warner PJ, Jiménez-Díaz R (1994) Use of *Lactobacillus*
834 *plantarum* LPCO10, a Bacteriocin Producer, as a Starter Culture in Spanish-Style
835 Green Olive Fermentations. *Appl Environ Microbiol* 60 (6):2059-2064
- 836 119. Ryan MP, Meaney WJ, Ross RP, Hill C (1998) Evaluation of lacticin 3147 and a teat
837 seal containing this bacteriocin for inhibition of mastitis pathogens. *Appl Environ*
838 *Microbiol* 64 (6):2287-2290

- 839 120. Ryan MP, Rea MC, Hill C, Ross RP (1996) An application in cheddar cheese
840 manufacture for a strain of *Lactococcus lactis* producing a novel broad-spectrum
841 bacteriocin, lacticin 3147. Appl Environ Microbiol 62 (2):612-619
- 842 121. Sashihara T, Kimura H, Higuchi T, Adachi A, Matsusaki H, Sonomoto K, Ishizaki A
843 (2000) A novel lantibiotic, nukacin ISK-1, of *Staphylococcus warneri* ISK-1: cloning
844 of the structural gene and identification of the structure. Biosci Biotechnol Biochem
845 64 (11):2420-2428
- 846 122. Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P (2008) The penicillin-binding
847 proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev 32
848 (2):234-258
- 849 123. Schaller K, Höltje JV, Braun V (1982) Colicin M is an inhibitor of murein
850 biosynthesis. J Bacteriol 152 (3):994-1000
- 851 124. Scheurwater EM, Burrows LL (2011) Maintaining network security: how
852 macromolecular structures cross the peptidoglycan layer. FEMS Microbiol Lett 318
853 (1):1-9
- 854 125. Schindler CA, Schuhardt VT (1964) Lysostaphin: A New Bacteriolytic Agent for the
855 *Staphylococcus*. Proc Natl Acad Sci U S A 51:414-421
- 856 126. Schmitt P, Wilmes M, Pugnière M, Aumelas A, Bachère E, Sahl HG, Schneider T,
857 Destoumieux-Garzón D (2010) Insight into invertebrate defensin mechanism of
858 action: oyster defensins inhibit peptidoglycan biosynthesis by binding to lipid II. J
859 Biol Chem 285 (38):29208-29216
- 860 127. Schneewind O, Fowler A, Faull KF (1995) Structure of the cell wall anchor of surface
861 proteins in *Staphylococcus aureus*. Science (New York, NY) 268 (5207):103-106

- 862 128. Schneider T, Kruse T, Wimmer R, Wiedemann I, Sass V, Pag U, Jansen A, Nielsen
863 AK, Mygind PH, Raventós DS, Neve S, Ravn B, Bonvin AM, De Maria L, Andersen
864 AS, Gammelgaard LK, Sahl HG, Kristensen HH (2010) Plectasin, a fungal defensin,
865 targets the bacterial cell wall precursor Lipid II. *Science* 328 (5982):1168-1172
- 866 129. Schneider T, Sahl HG (2010) An oldie but a goodie - cell wall biosynthesis as
867 antibiotic target pathway. *Int J Med Microbiol* 300 (2-3):161-169
- 868 130. Schöffler H, Braun V (1989) Transport across the outer membrane of *Escherichia coli*
869 K12 via the FhuA receptor is regulated by the TonB protein of the cytoplasmic
870 membrane. *Mol Gen Genet* 217 (2-3):378-383
- 871 131. Sit CS, Vederas JC (2008) Approaches to the discovery of new antibacterial agents
872 based on bacteriocins. *Biochem Cell Biol* 86 (2):116-123
- 873 132. Smith L, Hasper H, Breukink E, Novak J, Cerkasov J, Hillman JD, Wilson-Stanford S,
874 Orugunty RS (2008) Elucidation of the antimicrobial mechanism of mutacin 1140.
875 *Biochemistry* 47 (10):3308-3314
- 876 133. Stevens KA, Sheldon BW, Klapes NA, Klaenhammer TR (1991) Nisin treatment for
877 inactivation of *Salmonella* species and other gram-negative bacteria. *Appl Environ*
878 *Microbiol* 57 (12):3613-3615
- 879 134. Szekat C, Jack RW, Skutlarek D, Färber H, Bierbaum G (2003) Construction of an
880 expression system for site-directed mutagenesis of the lantibiotic mersacidin. *Appl*
881 *Environ Microbiol* 69 (7):3777-3783
- 882 135. Thumm G, Götz F (1997) Studies on prollystaphin processing and characterization
883 of the lysostaphin immunity factor (Lif) of *Staphylococcus simulans* biovar
884 *staphylolyticus*. *Mol Microbiol* 23 (6):1251-1265

885 136. Turner DL, Brennan L, Meyer HE, Lohaus C, Siethoff C, Costa HS, Gonzalez B,
886 Santos H, Suárez JE (1999) Solution structure of plantaricin C, a novel lantibiotic. Eur
887 J Biochem 264 (3):833-839

888 137. van Heijenoort J (2001) Recent advances in the formation of the bacterial
889 peptidoglycan monomer unit. Natural Product Reports 18 (5):503-519

890 138. van Kuijk S, Noll KS, Chikindas ML (2012) The species-specific mode of action of
891 the antimicrobial peptide subtilisin against *Listeria monocytogenes* Scott A. Lett Appl
892 Microbiol 54(1):52-58

893 139. Vollmer W (2008) Structural variation in the glycan strands of bacterial
894 peptidoglycan. FEMS Microbiol Rev 32 (2):287-306

895 140. Vollmer W, Blanot D, de Pedro MA (2008) Peptidoglycan structure and architecture.
896 FEMS Microbiol Rev 32 (2):149-167

897 141. Vollmer W, Pils H, Hantke K, Höltje JV, Braun V (1997) Pesticin displays
898 muramidase activity. J Bacteriol 179 (5):1580-1583

899 142. Wheeler R, Mesnage S, Boneca IG, Hobbs JK, Foster SJ (2011) Super-resolution
900 microscopy reveals cell wall dynamics and peptidoglycan architecture in ovococcal
901 bacteria. Mol Microbiol 82 (5):1096-1109

902 143. Wiedemann I, Böttiger T, Bonelli RR, Schneider T, Sahl HG, Martínez B (2006) Lipid
903 II-based antimicrobial activity of the lantibiotic plantaricin C. Appl Environ Microbiol
904 72 (4):2809-2814

905 144. Wiedemann I, Böttiger T, Bonelli RR, Wiese A, Hagge SO, Gutschmann T, Seydel U,
906 Deegan L, Hill C, Ross P, Sahl HG (2006) The mode of action of the lantibiotic

907 lactacin 3147--a complex mechanism involving specific interaction of two peptides
908 and the cell wall precursor lipid II. Mol Microbiol 61 (2):285-296
909 145. Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, Sahl
910 HG (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines
911 pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J
912 Biol Chem 276 (3):1772-1779
913 146. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415
914 (6870):389-395
915 147. Zeth K, Römer C, Patzer SI, Braun V (2008) Crystal structure of colicin M, a novel
916 phosphatase specifically imported by *Escherichia coli*. J Biol Chem 283 (37):25324-
917 25331
918

Figure legends

Fig.1 Scheme of the structure of the cell wall of Gram-positive (left) and Gram-negative (right) bacteria. CM: cytoplasmic membrane. PG: peptidoglycan. OM: outer membrane. NAG: *N*-acetylglucosamine. NAM: *N*-acetylmuramic acid. LPS: lipopolysaccharide

Fig.2 Mode of action of some cell wall-active bacteriocins. Square: *N*-acetylglucosamine. Triangle: *N*-acetylmuramic acid. CM: cytoplasmic membrane. PG: peptidoglycan. Within the PG, β 1-4 glycosidic bonds (horizontal lines) and cross-bridges (vertical lines). Boxes: detailed muropeptide composition of streptococcal (left) and staphylococcal (right) peptidoglycan

Fig.3 Overview of the role of lactococcin 972 (Lcn972) as a tool to study cell wall damage and resistance mechanisms in the industrial strain *Lactococcus lactis*, with the aim of improving performance in dairy fermentations. HK: histidin kinase. RR: response regulator. PG: peptidoglycan

Table 1 Examples of cell wall-active bacteriocins

Bacteriocin	Class^a	Singular features^b	Reference
Nisin	Ia Linear lantibiotic	Combines lipid II-mediated pore formation and inhibition of CW biosynthesis	[19]
Mersacidin	Ib Globular lantibiotic	Inhibits transglycosilation during CW biosynthesis	[22]
Plantaricin C	Ia/Ib Globular pore-forming lantibiotic	Shares structural/functional features with both nisin and mersacidin	[143]
Nukacin ISK-1	Ia/Ib Globular non-pore-forming lantibiotic	Binds to lipid II accumulating CW precursors	[2]
Lacticin 3147	Ic Multi-component lantibiotic	Combines pore formation and inhibition of CW biosynthesis in each peptide	[144]
Haloduracin	Ic Multi-component lantibiotic	Combines pore formation and inhibition of CW biosynthesis in each peptide	[102]
Lactococcin 972	IIIa Heat-sensitive	Binds to lipid II blocking the incorporation of CW precursors at the septum	[84]
Colicin M	IIIb Non-lytic large protein	Hydrolyses lipid II	[106]
Lysostaphin	IIIa Bacteriolytic large protein	Glycylglycine endopeptidase at the cross-bridge of staphylococcal PG	[55]
Zoozin A	IIIa Bacteriolytic large protein	Endopeptidase at the peptide side chain	[48]
Millericin B	IIIa Bacteriolytic large protein	Endopeptidase at the peptide side chain and cross-bridge	[10]
Pesticin	IIIa Bacteriolytic large protein	Hydrolyses glycan chains	[107]

^a According to Heng and Tagg [62]

^b CW: cell wall; PG: peptidoglycan